scholarly journals Layer-by-Layer Heparinization of the Cell Surface by Using Heparin-Binding Peptide Functionalized Human Serum Albumin

Materials ◽  
2018 ◽  
Vol 11 (5) ◽  
pp. 849 ◽  
Author(s):  
Guowei Song ◽  
Yaning Hu ◽  
Yusheng Liu ◽  
Rui Jiang
Keyword(s):  
Human Serum Albumin ◽  
Cell Surface ◽  
Serum Albumin ◽  
Human Serum ◽  
Layer By Layer ◽  
Heparin Binding ◽  
Binding Peptide

Radiolabeled IL-2-Human Serum Albumin Fusion Protein (Albuleukin™) as a Potential New Reagent for Radioimmunoimaging / Therapy of Hodgkin’s Lymphoma.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4633-4633
Author(s):  
Jan O. Staak ◽  
David Colcher ◽  
Jianyi Wang ◽  
Cynthia Sung ◽  
Andrew A. Raubitschek
Keyword(s):  
Human Serum Albumin ◽  
Cell Surface ◽  
Fusion Protein ◽  
Serum Albumin ◽  
Human Serum ◽  
Tumor Targeting ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Blood Clearance ◽  
Imaging Studies

Abstract Objectives: CD25 (IL-2Rα) is overexpressed on the cell surface by a variety of malignant diseases including Hodgkin’s lymphoma (HL) and its surrounding lymphoid infitrate. A soluble form of this receptor (sCD25) may limit a targeting agent’s ability to bind to the tumor cells which may result in decreased therapeutic efficacy. Albuleukin is a fusion protein of recombinant native IL-2 and human serum albumin with a molecular mass of 82kD. Albuleukin possesses the immunomodulatory characteristics of IL-2 with a significantly extended circulatory half-life and better localization in lymphocyte rich tissues than IL-2. We investigated the targeting and pharmacokinetic properties of Albuleukin in a human CD25+ HL xenograft model as a potential novel radioimmunodiagnostic/-therapeutic agent. Materials & Methods: Albuleukin was conjugated with a DOTA bifunctional chelating agent. DOTA-Albuleukin was radiolabeled with 111In (specific activity 3μCi/μg; 91–100% labeling efficiencies). Human HL (L540) tumor bearing nude mice were injected i.v. with 111In-Albuleukin (5μCi) with and without unlabeled humanized anti-CD25 (daclizumab; 5μg 4h prior) to investigate its potential impact on pharmacokinetics and tumor targeting. Mice were sacrificed at various time points and tumors, blood and major organs were collected and analyzed for radioactivity. Serum samples were analyzed by size exclusion chromatography (SEC-) HPLC. Serial whole body γ-imaging studies (15μCi) were also performed. Results: Biodistribution and imaging studies of 111In-Albuleukin exhibited rapid blood clearance (4%ID/g at 24h), specific tumor localization (18%ID/g at 24h) and favorable tumor:blood ratios (22:1 at 48h). Adding anti-CD25 MAb did not alter the biodistribution profile or targeting of Albuleukin. No breakdown products of Albuleukin or formation of complexes between Albuleukin and sCD25 (with or without anti-CD25) were detected by SEC-HPLC in the mouse serum. Conclusions: Unlike small MAb fragments of comparable size, Albuleukin did not accumulate in metabolizing organs such as liver and kidneys. The low affinity of Albuleukin to sCD25 may explain the absence of immunocomplexes, as we have observed with the radiolabeled anti-CD25 alone, and unaltered biodistribution when unlabeled anti-CD25 was added. The good tumor targeting of the Albuleukin may be due to the involvement of the cell surface high affinity receptor including beta- and gamma-chains. The rapid blood clearance in concert with low normal organ uptake and good tumor targeting as well as its presumed low immunogenicity in humans makes 111In-Albuleukin a potential new reagent for radioimmunoimaging, and possibly for treatment of CD25+ lymphoma utilizing 90Y.

Human Serum Albumin Nanotubes Comprising Layer-by-layer Assembly with Polycation

2008 ◽  
Vol 37 (9) ◽  
pp. 972-973 ◽  
Author(s):  
Gang Lu ◽  
Eishun Tsuchida ◽  
Teruyuki Komatsu
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Layer By Layer ◽  
Layer By Layer Assembly ◽  
Layer Assembly

II. Lokalisation der Placenta mit 113Inm- Human-Serum-Albumin

1969 ◽  
Vol 08 (01) ◽  
pp. 15-21 ◽  
Author(s):  
K. E. Scheer ◽  
J. Heep ◽  
W. Maier-Borst ◽  
W. J. Lorenz ◽  
H. Sinn ◽  
...  
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Vena Cava ◽  
Placenta Praevia ◽  
Wird Eine

ZusammenfassungNach tierexperimentellen Voruntersuchungen wurde die Placentographie mit trägerfreiem 113Inm -HSA als klinische Methode eingeführt. Vor Amniocentesen und bei Verdacht auf Placenta praevia werden Placentographien geschrieben. Den Schwangeren wird eine Aktivität von 500 μCi in die Cubitalvene injiziert. Die der Aktivität entsprechende Indiummenge ist kleiner als 0,1 ng. Die fetale Strahlenbelastung liegt unter lOmrad. Bei Anwendung von 113Inm-HSA entfällt eine Blockade der mütterlichen und fetalen Schilddrüsen. Die genaue Abgrenzung einer Placenta praevia wird nicht durch eine Blasenaktivität beeinträchtigt.Es wurden bisher 19 Placentalokalisationen durchgeführt. In allen Fällen konnte der Placentasitz eindeutig festgestellt werden. Bedingt durch die lange Liegezeit beim Aufnehmen eines Szintigramms kam es in zwei Fällen zu einem Vena-Cava-Kompressions-Syndrom. Zur Verhinderung dieser klinischen Zwischenfälle werden inzwischen Placentographien mit der Anger-Kamera aufgenommen. Mit Hilfe des divergierenden Kollimators konnte der gesamte Abdominalbereich erfaßt werden. Die Aufnahmezeit konnte auf 7 — 10 Minuten verkürzt werden. Die intravenöse injizierte Aktivität betrug bei dieser Methode ebenfalls 500 μCi. Der diagnostische Aussagewert der Kamerabilder ist szintigraphischen Aufnahmen gleichwertig.

Sign in / Sign up

Export Citation Format

Share Document